🏛️ Verified NIH Record • Updated 2026-03-17
FT819 in Subjects With B-cell Malignancies (NCT04629729)
A Phase I Study of FT819 in Subjects With B-cell Malignancies
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Fate Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Mayo Arizona — Phoenix, Arizona
- UC Davis — Davis, California
- Scripps Green Hospital — La Jolla, California
- UCLA Ronald Reagan Medical Center — Los Angeles, California
- Stanford Cancer Institute — Palo Alto, California
- University of Florida — Gainesville, Florida
- Mayo Florida — Jacksonville, Florida
- University of Iowa — Iowa City, Iowa
- The University of Kansas Cancer Center — Westwood, Kansas
- Norton Cancer Institute, St. Matthews Campus — Louisville, Kentucky
- Mayo Minnesota — Rochester, Minnesota
- University of Nebraska Medical Center — Omaha, Nebraska
- Hackensack University Medical Center — Hackensack, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- Oregon Health & Sciences University — Portland, Oregon
- MD Anderson Cancer Center — Houston, Texas
- University of Wisconsin-Madison — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, B-Cell
- Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — New York, New York
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — Scottsdale, Arizona
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies — Duarte, California
- A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas — Denver, Colorado
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma — Vancouver, British Columbia
Explore by condition: All Lymphoma, B-Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.